期刊
ONCOLOGIST
卷 8, 期 3, 页码 278-292出版社
ALPHAMED PRESS
DOI: 10.1634/theoncologist.8-3-278
关键词
neuroblastoma; tumor biology; retinoids; immunotherapy; risk-based therapy
类别
资金
- NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER
- NCI NIH HHS [5P30CA60553] Funding Source: Medline
Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior ranging from spontaneous remission to rapid tumor progression and death. To a large extent, outcome can be predicted by the stage of disease and the age at diagnosis. However, the molecular events responsible for the variability in response to treatment and the rate of tumor growth remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to the understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. The Children's Oncology Group recently developed a Neuroblastoma Risk Stratification System, that is currently in use for treatment stratification purposes, based on clinical and biologic factors that are strongly predictive of outcome. This review discusses the current risk-based treatment approaches for children with neuroblastoma and recent advances in biologic therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据